1.63
+5.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 22nd Century Group
From its filings with the US Securities and Exchange Commission
22nd Century Group is based in Williamsville, Indiana and is incorporated in Florida. Its shares trade on Nasdaq under the ticker XXII. The SEC classifies its business as cigarettes. In the fiscal year to 31 December 2025, it reported revenue of $17.6m and a net loss of $5.1m. At that date it held total assets of $27.0m and shareholders' equity of $15.8m.
22nd Century Group, Inc. is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. We manufacture and distribute the only combustible tobacco products containing minimally or non-addictive levels of nicotine that are authorized by the US Food and Drug Administration (FDA) for retail purchase. We also provide turnkey contract manufacturing of cigarettes and filtered cigars for other established tobacco brands.
We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them decide their consumption of nicotine. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering the nicotine drug to addicted smokers, we offer smokers the option to make their own informed and health conscious productive choices, including the choice to avoid addictive levels of nicotine altogether and help adult smokers smoke less.
Since the US Surgeon General first warned of the dangers of cigarette smoking in 1964, the debate over tobacco health harm has been largely dominated by two powerful voices: Big Tobacco and the US Government. After decades of litigation, lobbying and lawmaking, the major tobacco producers still decide the nicotine levels contained in the tobacco products consumed by smokers.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Tobacco
- Listed since
- 17 Oct 2006
- Employees
- 32
- Website
- xxiicentury.com ↗
- Head office
- 8560 MAIN STREET, WILLIAMSVILLE, IN, 14221
- Incorporated in
- FL
- Classification
- Cigarettes
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Lawrence FirestoneChairman of the Board, Chief Executive Officer, since 2023$426,679
- Mr. Daniel OttoChief Financial Officer$369,982
- Mr. Robert ManfredoniaExecutive Vice President - Sales and Marketing$109,042
- Mr. Scott MarionVice President - Manufacturing Operations$266,584
- Mr. Jonathan StaffeldtGeneral Counsel, Corporate Secretary$373,941
- Mr. Andrew ArnoLead Independent Director$30,000
- Mr. Anthony JohnsonIndependent Director$17,500
- Ms. Lucille SalhanyIndependent Director$17,500
- Mr. Matt KrepsInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 16
- Social
- 35
- Governance
- 15
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates in the tobacco sector with a unique biotechnology focus.
- It develops technology to modify nicotine levels in tobacco plants.
- Research cigarettes are produced for the National Institute on Drug Abuse.
Weaknesses
- The company has a small workforce of only thirty-two employees.
- It faces challenges in the consumer staples industry due to regulatory pressures.
- Reliance on contract manufacturing may limit direct control over production.
Opportunities
- Growing demand for less harmful tobacco products offers market expansion.
- Development of smoking cessation aids like X-22 presents new revenue streams.
- Genetic engineering technology can be applied to cannabis plant cannabinoid levels.
Threats
- Strict government regulations on tobacco products pose significant operational risks.
- Changing consumer preferences away from traditional smoking habits threaten sales.
- Competitive pressure from other biotechnology and tobacco companies is intense.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.